Enalare Therapeutics Inc., a biopharmaceutical company, announced that the Food and Drug Administration (FDA) has granted it's lead compound, ENA-001, rare pediatric disease designation for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results